However, medications to lower plasma glucose and improve insulin resistance (including metformin and dapagliflozin) in adults with overweight/obesity and prediabetes did not decrease fasting plasma LEAP2 over 13 weeks [67]. This evidence concerns the gene LEAP2 and obesity due to melanocortin 4 receptor deficiency.